Keywords
Ultraviolet Radiation
Keratosis
Topical Therapies
Dermatological Clinical Diagnosis
How to Cite
Abstract
Background: Actinic keratosis (AK) is a pre-malignant skin lesion common in sun-exposed areas, especially in fair-skinned and elderly individuals. Related to chronic exposure to UV radiation, it is associated with mutations in the TP53 gene, compromising cell control. Although many lesions remain stable, up to 10% can develop into squamous cell carcinoma, highlighting the importance of early diagnosis and appropriate treatment. Diagnosis is clinical, with histopathological confirmation in suspected cases. New therapeutic approaches, such as innovative topical agents and immunomodulatory techniques, have shown promise in the prevention and treatment of AK.
Aim: To synthesize clinical evidence about advances in the treatment of AK.
Method: This study was designed as an exploratory study, based on the literature review method with evidence synthesis. The database chosen to select the studies was PUBMED, using the following search strategy: actinic[title] AND keratos*[title]. Studies published in the last year (2024-2025) were evaluated, and any randomized clinical study that discussed the proposed topic was initially included in the sample. Results: Initially, 11 studies were identified. After reviewing the titles and abstracts, none were excluded.
Conclusions: The studies analyzed showed promising advances in the treatment of AK, highlighting effective and safe approaches such as the use of a gel containing a cytosolic phospholipase A2 inhibitor, the combination of 5-fluorouracil with daylight photodynamic therapy (DL-PDT) and home DL-PDT. The occlusive application of methyl aminolevulinate and two-step photodynamic therapy have also been shown to be effective strategies for improving therapeutic response and reducing pain. These interventions offer viable and safe alternatives, with a high level of satisfaction and the potential to increase adherence to treatment.
References
BIERHOFF, E. et al. High efficacy of red light photodynamic therapy with 10 % aminolevulinic acid gel irrespective of the extent of keratinocyte atypia in actinic keratosis - exploratory post-hoc analysis of three pivotal phase III trials. Photodiagnosis and Photodynamic Therapy, v. 50, p. 104361, dez. 2024.
CHEN, H. et al. Liquid nitrogen cryotherapy effectively and safely improves response of thick actinic keratoses lesions by 5-aminolevulinic acid-based photodynamic therapy: A randomized, prospective, single-blind trial. Photodiagnosis and Photodynamic Therapy, v. 50, p. 104363, dez. 2024.
FREDMAN, G. et al. Prebiotic and panthenol-containing dermocosmetic improves tolerance from artificial daylight photodynamic therapy: A randomized controlled trial in patients with actinic keratosis. Photodiagnosis and Photodynamic Therapy, v. 50, p. 104394, dez. 2024.
GEORGE, C. D. et al. Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis. The British Journal of Dermatology, v. 190, n. 4, p. 465–476, 15 mar. 2024.
JAMES, W. D. et al. Andrews’ Diseases of the Skin E-Book: Clinical Dermatology. [s.l.] Elsevier Health Sciences, 2024.
KITAMURA, R. H. et al. Evaluation of four regimens of methyl aminolevulinate mediated by red light to treat actinic keratoses: A randomized controlled clinical protocol. PloS One, v. 20, n. 2, p. e0318109, 2025.
LYLE, R. E.; TRAN, L. H.; EISEN, D. B. Innovations in Actinic Keratosis. Dermatologic Clinics, v. 43, n. 1, p. 77–94, jan. 2025.
MALVEHY, J. et al. Actinic keratosis: Current challenges and unanswered questions. Journal of the European Academy of Dermatology and Venereology: JEADV, v. 38 Suppl 5, p. 3–11, jul. 2024.
NAIR, C. Prevention, diagnosis and treatment of actinic keratosis. Prescriber, v. 35, n. 2, p. 19–24, 2024.
NALDI, L.; CASSALIA, F. Actinic keratosis epidemiology: the good, the bad and the ugly. The British Journal of Dermatology, v. 190, n. 4, p. 457–458, 15 mar. 2024.
ORTNER, V. K. et al. Mobile health technologies in an interventional hybrid study on actinic keratosis: Results from an early phase randomized controlled trial investigating the safety and efficacy of a cytosolic phospholipase A2 inhibitor gel in photodamaged skin. Experimental Dermatology, v. 33, n. 4, p. e15068, abr. 2024.
PHILIPP-DORMSTON, W. G. et al. Patient-centered management of actinic keratosis. Results of a multi-center clinical consensus analyzing non-melanoma skin cancer patient profiles and field-treatment strategies. The Journal of Dermatological Treatment, v. 31, n. 6, p. 576–582, set. 2020.
POOSTIYAN, N. et al. Clinical and Dermoscopic Comparison of the Efficacy and Safety of 5% Fluorouracil Topical Cream and 1% Niacinamide Topical Gel in the Treatment of Actinic Keratosis: A Randomized Controlled Trial. Journal of Cosmetic Dermatology, v. 24, n. 2, p. e16676, fev. 2025.
REINEHR, C. P. H.; BAKOS, R. M. Ceratoses actínicas: revisão dos aspectos clínicos, dermatoscópicos e terapêuticos. Anais Brasileiros de Dermatologia (Portuguese), v. 94, n. 6, p. 637–657, 1 nov. 2019.
SAENZ-GUIRADO, S. et al. Home- vs clinic-based daylight photodynamic therapy with 5-aminolevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis: A randomized, single-blind, prospective study. Photodiagnosis and Photodynamic Therapy, v. 46, p. 104031, abr. 2024.
SCHMITZ, L.; BROGANELLI, P.; BOADA, A. Classifying Actinic Keratosis: What the Reality of Everyday Clinical Practice Shows Us. Journal of drugs in dermatology: JDD, v. 21, n. 8, p. 845–849, 1 ago. 2022.
SOUZA, M. T. DE; SILVA, M. D. DA; CARVALHO, R. DE. Revisão integrativa: o que é e como fazer. einstein (São Paulo), v. 8, p. 102–106, mar. 2010.
THAMM, J. R.; SCHUH, S.; WELZEL, J. Epidemiology and Risk Factors of Actinic Keratosis. What is New for The Management for Sun-Damaged Skin. Dermatology Practical & Conceptual, v. 14, n. 3 S1, p. e2024146S, 1 set. 2024.
THAMM, J. R.; WELZEL, J.; SCHUH, S. Diagnosis and therapy of actinic keratosis. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG, v. 22, n. 5, p. 675–690, maio 2024.
TRAVE, I. et al. The impact of occlusive vs non-occlusive application of methyl aminolevulinate on the efficacy and tolerability of daylight photodynamic therapy for actinic keratosis. Photodiagnosis and Photodynamic Therapy, v. 46, p. 104049, abr. 2024.
ULRICH, M. et al. Effective treatment of actinic keratosis on the hands with red light photodynamic therapy using BF-200 ALA. Photodiagnosis and Photodynamic Therapy, v. 49, p. 104280, out. 2024.
WANG, Y. et al. Clinical trial of two-step photodynamic therapy for reduced pain in the treatment of precancerous squamous lesions (Actinic keratoses). Photodiagnosis and Photodynamic Therapy, v. 49, p. 104294, out. 2024a.
WANG, Z. et al. Advancements in elucidating the pathogenesis of actinic keratosis: present state and future prospects. Frontiers in Medicine, v. 11, p. 1330491, 2024b.
WIEGELL, S. R. et al. Pre-treatment with topical 5-fluorouracil increases the efficacy of daylight photodynamic therapy for actinic keratoses - A randomized controlled trial. Photodiagnosis and Photodynamic Therapy, v. 46, p. 104069, abr. 2024.
ZOU, D.-D. et al. Single-cell sequencing highlights heterogeneity and malignant progression in actinic keratosis and cutaneous squamous cell carcinoma. eLife, v. 12, p. e85270, 15 dez. 2023.
This work is licensed under a Creative Commons Attribution 4.0 International License.